Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA accepts DSCO's Surfaxin NDA

The FDA accepted for filing an NDA from

Read the full 82 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE